Disease · MONDO_0015643

photosensitive epilepsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. photosensitive epilepsy. Diseases, record MONDO_0015643. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015643

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: photosensitive epilepsy; Open Targets
Open Targets ID: MONDO_0015643; Open Targets
Other names: photoparoxysmal response; Open Targets
Disease Ontology: DOID:0060281; Disease Ontology
Orphanet: ORPHA:166409; Orphanet
Highest stage of its drugs: Phase 2/3, for 2 of its 10 drugs, from ClinicalTrials.gov; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BRIVARACETAM	CHEMBL607400	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALPRAZOLAM	CHEMBL661	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
APINOCALTAMIDE	CHEMBL4217292	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CENOBAMATE	CHEMBL3989949	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DARIGABAT	CHEMBL3647536	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
JNJ-26489112	CHEMBL3092995	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SELURAMPANEL	CHEMBL3545042	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets41

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 41

See all 41 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02564029	PF-06372865 in Subjects With Photosensitive Epilepsy	Phase 2	7	2018-03-14	Reflex Epilepsy, Photosensitive	DARIGABAT, LORAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT02351115	Staccato Alprazolam and Photoparoxysmal Response	Phase 2	5	2021-08-10	Epilepsy	ALPRAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT00401648	Effect of Brivaracetam in Photosensitive Epileptic Subjects	Phase 2	20		Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT03580707	Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint	Phase 2/3	16		Photosensitive Epilepsy	BRIVARACETAM, LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT00784212	Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy	Phase 2	13		Photosensitive Epilepsy	SELURAMPANEL	Its record names the disease	ClinicalTrials.gov
NCT00579384	A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy	Phase 2	12		Photosensitive Epilepsy	JNJ-26489112	Its record names the disease	ClinicalTrials.gov
NCT00616148	Efficacy of YKP3089 in Patients With Photosensitive Epilepsy	Phase 2	11		Epilepsy	CENOBAMATE	Its record names the disease	ClinicalTrials.gov
NCT03239691	A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients	Phase 2	5		Photosensitive Epilepsy	APINOCALTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05678881	Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy	Phase 1	2		Epilepsy	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32949370	DERIVED	1	PubMed
31292226	DERIVED	1	PubMed
30877186	DERIVED	1	PubMed
25963722	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015643

GET https://conductscience.org/api/diseases/v1/MONDO_0015643/targets?page=2

API reference For AI assistants